Annen D J, Stürmer J
Universitätsaugenklinik Zürich.
Klin Monbl Augenheilkd. 1995 May;206(5):300-2. doi: 10.1055/s-2008-1035446.
The application of anti fibroses agents during glaucoma surgery leads to more satisfactory results with lower i.o. pressure, yet eliciting complications in wound healing, avascular filtering blebs and frequent chronic hypotonias. In patients with lower risk for failure a reduction of concentration and application time of Mitomycin C should minimise side effects while maintaining the beneficial effect of lower intraocular pressure.
34 eyes of 32 patients (age 72 +/- 8) underwent trabeculectomy (14 combined with phacoemulsification and implantation of a foldable posterior chamber lens). During filtering surgery, Mitomycin C (0.2 mg/ml for 1 min) was applied after preparation of the scleral flap. An 11.5 +/- 5.0 (3-21), month followup, 30 (34) eyes (88.2%) had an i.o. pressure of < or = 21 mm Hg (14.0 +/- 4.3 mm Hg at the last control) without additional glaucoma medications.
The majority of filtering blebs (30/34; 88.2%) were well vascularised, often showing polycystic degenerations near the limbus. Only 3 eyes developed an avascular filtering bleb. No persisting leaks were observed and only 2 of 34 eyes (5.9%) developed short transient hypotonia (IOP < 6 mm Hg).
Adjunctive treatment with low concentration of Mitomycin C during filtering surgery results in good i.o. pressure with little risk of avascular bleb development. A prospective, randomised trial is required to assess the safety and efficacy of adjuvantive Mitomycin C treatment in low risk filtering surgery.
青光眼手术中应用抗纤维化药物可使眼压降低,从而获得更满意的效果,但会引发伤口愈合、无血管滤过泡及频繁慢性低眼压等并发症。对于手术失败风险较低的患者,降低丝裂霉素C的浓度和应用时间应能在维持降低眼压有益效果的同时将副作用降至最低。
32例患者(年龄72±8岁)的34只眼接受了小梁切除术(14例联合超声乳化及植入可折叠后房型人工晶状体)。在滤过手术中,巩膜瓣制备完成后应用丝裂霉素C(0.2mg/ml,持续1分钟)。随访11.5±5.0(3 - 21)个月,30只(34只眼中的)眼(88.2%)眼压≤21mmHg(末次检查时为14.0±4.3mmHg),无需额外使用青光眼药物。
大多数滤过泡(30/34;88.2%)血管化良好,常在角膜缘附近出现多囊样变性。仅3只眼形成了无血管滤过泡。未观察到持续性渗漏,34只眼中仅2只(5.9%)出现短暂性低眼压(眼压<6mmHg)。
滤过手术中使用低浓度丝裂霉素C辅助治疗可使眼压良好控制,无血管滤过泡形成风险低。需要进行一项前瞻性随机试验来评估辅助性丝裂霉素C治疗在低风险滤过手术中的安全性和有效性。